145 related articles for article (PubMed ID: 2571966)
21. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
Cuny M; Simony-Lafontaine J; Rouanet P; Grenier J; Valles H; Lavaill R; Louason G; Causse A; Lequeux N; Thierry C
Oncol Res; 1994; 6(4-5):169-76. PubMed ID: 7841539
[TBL] [Abstract][Full Text] [Related]
22. Expression of Bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon.
Flohil CC; Janssen PA; Bosman FT
J Pathol; 1996 Apr; 178(4):393-7. PubMed ID: 8691316
[TBL] [Abstract][Full Text] [Related]
23. Regulation of expression and transforming ability of the c-erbB-2 gene.
Matsuda S; Akiyama T; Yamada Y; Ishii S; Aizawa S; Mori S; Toyoshima K; Yamamoto T
Princess Takamatsu Symp; 1989; 20():93-101. PubMed ID: 2577338
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
Brysch W; Magal E; Louis JC; Kunst M; Klinger I; Schlingensiepen R; Schlingensiepen KH
Cancer Gene Ther; 1994 Jun; 1(2):99-105. PubMed ID: 7621247
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.
Liu C; Tsao MS
Am J Pathol; 1993 Apr; 142(4):1155-62. PubMed ID: 8097369
[TBL] [Abstract][Full Text] [Related]
26. c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression.
Thompson MA; Rosenthal MA; Ellis SL; Friend AJ; Zorbas MI; Whitehead RH; Ramsay RG
Cancer Res; 1998 Nov; 58(22):5168-75. PubMed ID: 9823328
[TBL] [Abstract][Full Text] [Related]
27. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa.
Gianani R; Jarboe E; Orlicky D; Frost M; Bobak J; Lehner R; Shroyer KR
Hum Pathol; 2001 Jan; 32(1):119-25. PubMed ID: 11172305
[TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues.
Lee H; Maihle NJ
Oncogene; 1998 Jun; 16(25):3243-52. PubMed ID: 9681822
[TBL] [Abstract][Full Text] [Related]
29. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue.
Corbett IP; Henry JA; Angus B; Watchorn CJ; Wilkinson L; Hennessy C; Gullick WJ; Tuzi NL; May FE; Westley BR
J Pathol; 1990 May; 161(1):15-25. PubMed ID: 1973458
[TBL] [Abstract][Full Text] [Related]
30. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.
Hynes NE
Semin Cancer Biol; 1993 Feb; 4(1):19-26. PubMed ID: 8095411
[TBL] [Abstract][Full Text] [Related]
31. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
Tan M; Yao J; Yu D
Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
[TBL] [Abstract][Full Text] [Related]
33. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa.
Ramsay RG; Thompson MA; Hayman JA; Reid G; Gonda TJ; Whitehead RH
Cell Growth Differ; 1992 Oct; 3(10):723-30. PubMed ID: 1445802
[TBL] [Abstract][Full Text] [Related]
34. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas.
Park JB; Rhim JS; Park SC; Kimm SW; Kraus MH
Cancer Res; 1989 Dec; 49(23):6605-9. PubMed ID: 2573419
[TBL] [Abstract][Full Text] [Related]
35. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.
Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ
Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
37. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
38. Immunocytochemical localization of c-erbB-2 protein in transitional cell carcinoma of the urinary bladder.
Coombs LM; Oliver S; Sweeney E; Knowles M
J Pathol; 1993 Jan; 169(1):35-42. PubMed ID: 8094432
[TBL] [Abstract][Full Text] [Related]
39. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Engelhardt M; Drullinsky P; Guillem J; Moore MA
Clin Cancer Res; 1997 Nov; 3(11):1931-41. PubMed ID: 9815582
[TBL] [Abstract][Full Text] [Related]
40. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
